Dopamine D<sub>1</sub> Agonists: First Potential Treatment for Late-Stage Parkinson’s Disease

Dopamine D<sub>1</sub> Agonists: First Potential Treatment for Late-Stage Parkinson’s Disease

Current pharmacotherapy has limited efficacy and/or intolerable side effects in late-stage Parkinson’s disease (LsPD) patients whose daily life depends primarily on caregivers and palliative care. Clinical metrics inadequately gauge efficacy in LsPD patients. We explored if a D<sub>1/5</sub...

Full description

Bibliographic Details
Main Authors: Mechelle M. Lewis, Lauren J. Van Scoy, Sol De Jesus, Jonathan G. Hakun, Paul J. Eslinger, Julio Fernandez-Mendoza, Lan Kong, Yang Yang, Bethany L. Snyder, Natalia Loktionova, Sridhar Duvvuri, David L. Gray, Xuemei Huang, Richard B. Mailman
Format: Article
Language:English
Published: MDPI AG 2023-05-01
Series:Biomolecules
Subjects:
dopamine D<sub>1</sub> agonists
late-stage Parkinson’s disease
dopamine D<sub>1</sub> receptors
clinical trial
Online Access:https://www.mdpi.com/2218-273X/13/5/829

Internet

https://www.mdpi.com/2218-273X/13/5/829

Similar Items